• 1
    Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001; 33: 13531357.
  • 2
    Taylor-Robinson SD, Toledano MB, Arora S, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut. 2001; 48: 816820.
  • 3
    Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002; 37: 806813.
  • 4
    Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003; 53: 526.
  • 5
    Kornfeld D, Ekbom A, Ihre T. Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study. Scand J Gastroenterol. 1997; 32: 10421045.
  • 6
    Broome U, Olsson R, Loof L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996; 38: 610615.
  • 7
    Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 2002; 51 Suppl 6: VI1VI9.
  • 8
    de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999; 341: 13681378.
  • 9
    Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatology. 2003; 37: 961969.
  • 10
    Yoon JH, Gores GJ. Diagnosis, staging, and treatment of cholangiocarcinoma. Curr Treat Options Gastroenterol. 2003; 6: 105112.
  • 11
    Gores GJ. Early detection and treatment of cholangiocarcinoma. Liver Transplant. 2000; 6: S30S34.
  • 12
    Kaya M, de Groen PC, Angulo P, et al. Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experience. Am J Gastroenterol. 2001; 96: 11641169.
    Direct Link:
  • 13
    Siqueira E, Schoen RE, Silverman W, et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc. 2002; 56: 4047.
  • 14
    Hultcrantz R, Olsson R, Danielsson A, et al. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol. 1999; 30: 669673.
  • 15
    Bjornsson E, Kilander A, Olsson R. CA19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver. 1999; 19: 501508.
  • 16
    Fisher A, Theise ND, Min A, et al. CA19-9 does not predict cholangiocarcinoma in patients with primary sclerosing cholangitis undergoing liver transplantation. Liver Transplant Surg. 1995; 1: 9498.
  • 17
    Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology. 2000; 31: 711.
  • 18
    Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology. 1995; 108: 865869.
  • 19
    Ker CG, Chen JS, Lee KT, Sheen PC, Wu CC. Assessment of serum and bile levels of CA19-9 and CA125 in cholangitis and bile duct carcinoma. J Gastroenterol Hepatol. 1991; 6: 505508.
  • 20
    Nakeeb A, Lipsett PA, Lillemoe KD, et al. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma. Am J Surg. 1996; 171: 147152; discussion, 152–153.
  • 21
    Chen CY, Shiesh SC, Tsao HC, Lin XZ. The assessment of biliary CA125, CA19-9 and CEA in diagnosing cholangiocarcinoma—the influence of sampling time and hepatolithiasis. Hepatogastroenterology. 2002; 49: 616620.
  • 22
    Chen CY, Lin XZ, Tsao HC, Shiesh SC. The value of biliary fibronectin for diagnosis of cholangiocarcinoma. Hepatogastroenterology. 2003; 50: 924927.
  • 23
    Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer. 2003; 3: 267275.
  • 24
    Pandey A, Mann M. Proteomics to study genes and genomes. Nature. 2000; 405: 837846.
  • 25
    Clarke W, Zhang Z, Chan DW. The application of clinical proteomics to cancer and other diseases. Clin Chem Lab Med. 2003; 41: 15621570.
  • 26
    Kristiansen TZ, Bunkenborg J, Gronborg M, et al. A proteomic analysis of human bile. Mol Cell Proteomics. 2004; 7: 715728.
  • 27
    Cesinaro AM, Natoli C, Grassadonia A, Tinari N, Iacobelli S, Trentini GP. Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. J Invest Dermatol. 2002; 119: 187190.
  • 28
    Marchetti A, Tinari N, Buttitta F, et al. Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in Stage I non-small cell lung cancer patients. Cancer Res. 2002; 62: 25352539.
  • 29
    Fusco O, Querzoli P, Nenci I, et al. 90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells. Int J Cancer. 1998; 79: 2326.
  • 30
    Kunzli BM, Berberat PO, Zhu ZW, et al. Influences of the lysosomal associated membrane proteins (Lamp-1, Lamp-2) and Mac-2 binding protein (Mac-2-BP) on the prognosis of pancreatic carcinoma. Cancer. 2002; 94: 228239.
  • 31
    Shimonishi T, Miyazaki K, Kono N, et al. Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma. Hum Pathol. 2001; 32: 302310.
  • 32
    Tinari N, Kuwabara I, Huflejt ME, Shen PF, Iacobelli S, Liu FT. Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. Int J Cancer. 2001; 91: 167172.
  • 33
    Sasaki T, Brakebusch C, Engel J, Timpl R. Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds β1 integrins, collagens and fibronectin. EMBO J. 1998; 17: 16061613.
  • 34
    Gentiloni N, Caradonna P, Costamagna G, et al. Pancreatic juice 90K and serum CA19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. Am J Gastroenterol. 1995; 90: 10691072.
  • 35
    Iacovazzi PA, Trisolini A, Barletta D, Elba S, Manghisi OG, Correale M. Serum 90K/MAC-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: a comparison with alpha-fetoprotein. Clin Chem Lab Med. 2001; 39: 961965.
  • 36
    Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res. 2000; 6: 13891393.
  • 37
    Manley S, Mucci NR, De Marzo AM, Rubin MA. Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome: the prostate Specialized Program of Research Excellence model. Am J Pathol. 2001; 159: 837843.
  • 38
    DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44: 837845.
  • 39
    Izrael D. Use of the ROC curve and the bootstrap in comparing weighted logistic regression models. In: SAS Institute. Proceedings of the 27th Annual SAS Users Group International Conference. Cary, NC: SAS Institute, 2002.
  • 40
    de Bellis M, Fogel EL, Sherman S, et al. Influence of stricture dilation and repeat brushing on the cancer detection rate of brush cytology in the evaluation of malignant biliary obstruction. Gastrointest Endosc. 2003; 58: 176182.
  • 41
    Kubicka S, Kuhnel F, Flemming P, et al. K-ras mutations in the bile of patients with primary sclerosing cholangitis. Gut. 2001; 48: 403408.
  • 42
    Uchida N, Tsutsui K, Ezaki T, et al. Combination of assay of human telomerase reverse transcriptase mRNA and cytology using bile obtained by endoscopic transpapillary catheterization into the gallbladder for diagnosis of gallbladder carcinoma. Am J Gastroenterol. 2003; 98: 24152419.
    Direct Link:
  • 43
    Chen CY, Shiesh SC, Wu SJ. Rapid detection of K-ras mutations in bile by peptide nucleic acid-mediated PCR clamping and melting curve analysis: comparison with restriction fragment length polymorphism analysis. Clin Chem. 2004; 50: 481489.
  • 44
    Kittl EM, Hofmann J, Hartmann G, et al. Serum protein 90K/Mac-2BP is an independent predictor of disease severity during hepatitis C virus infection. Clin Chem Lab Med. 2000; 38: 205208.
  • 45
    Hansel DE, Rahman A, Hidalgo M, et al. Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol. 2003; 163: 217229.